Which is the most common mechanism of action among the antiparkinsonian drugs currently used as first-line or adjunctive therapy in Parkinson's disease?

Explanation

## Most Common Mechanism in Parkinsonism Therapy **Key Point:** Dopamine replacement (via levodopa) and dopaminergic agonism form the backbone of Parkinson's disease treatment and are by far the most frequently prescribed and clinically effective antiparkinsonian mechanisms. ### Dopaminergic Agents: The Cornerstone of Therapy **High-Yield:** Dopaminergic drugs are: - **First-line agents** for symptomatic management - **Most potent** in reducing cardinal symptoms (bradykinesia, rigidity, tremor) - **Used in >90%** of Parkinson's patients at some point - **Available in multiple formulations** (immediate-release, extended-release, transdermal, subcutaneous) ### Classification of Dopaminergic Agents | Agent Class | Examples | Mechanism | Frequency of Use | |---|---|---|---| | **Levodopa (L-DOPA)** | Levodopa + carbidopa/benserazide | Dopamine precursor; crosses BBB | Most common, gold standard | | **Dopamine agonists** | Bromocriptine, ropinirole, pramipexole, rotigotine | Direct D₁/D₂ receptor agonism | Very common, especially early disease | | **MAO-B inhibitors** | Selegiline, rasagiline | Reduce dopamine catabolism | Common adjunct | | **COMT inhibitors** | Entacapone, tolcapone | Reduce peripheral L-DOPA metabolism | Adjunctive in motor fluctuations | | **Anticholinergics** | Benztropine, trihexyphenidyl | Block muscarinic M₁ receptors | Declining use (older agents) | **Mnemonic:** **LARD** — Levodopa, Agonists, Rasagiline/selegiline (MAO-B), DOPA decarboxylase inhibitors (carbidopa) ### Why Dopaminergic Therapy Dominates 1. **Pathophysiology:** Parkinson's disease is fundamentally a **dopamine deficiency** in the nigrostriatal pathway (>60% loss of dopamine neurons by symptom onset) 2. **Efficacy:** Dopaminergic agents directly address the underlying neurochemical deficit 3. **Symptom coverage:** Effective against all cardinal features (tremor, rigidity, bradykinesia, postural instability) 4. **Clinical evidence:** Strongest evidence base for symptomatic benefit ### Adjunctive Mechanisms (Secondary Roles) **Anticholinergics** — historically used; now reserved for tremor-predominant disease or young patients; less effective than dopaminergic agents; higher adverse effect burden. **MAO-B inhibitors** — adjunctive role; modest symptomatic benefit; neuroprotective potential (unproven); used to extend levodopa effect or delay need for higher doses. **COMT inhibitors** — adjunctive only; used to reduce motor fluctuations in advanced disease; never monotherapy. **Clinical Pearl:** While anticholinergics were the mainstay of Parkinson's treatment in the pre-levodopa era (1960s), they are now rarely used as monotherapy because dopaminergic agents are far superior in efficacy and tolerability.